Synthetix Pharmaceuticals Patent Application: Immunoglobulin Chimeric Monomer-Dimer Heterodimers

The present invention relates to immunoglobulin chimeric monomer-dimer heterodimers. The present invention relates to chimeric monomer-dimer heterodimeric proteins, wherein said protein comprises a first and second polypeptide chain, wherein said first chain comprises at least a portion of an immunoglobulin constant region and a bioactive molecule, wherein said second chain comprises at least a portion of an immunoglobulin constant region, does not contain the bioactive molecule of the first chain. The present invention also relates to methods of using and preparing the chimeric monomer-dimer heterodimeric proteins of the present invention.


Synthetix Pharmaceuticals Patent Application: Immunoglobulin Chimeric Monomer-Dimer Heterodimers - cover page
Category
Other products
Document type
Other
Language
Chinese
Pages
84
File format
PDF
File size
1.8 MB
Published
15 November, 2023
Updated
15 November, 2023
MD5 checksum
F58680A7E35248167842AA7D4866B798

About this manual

The provided text is a patent application document (CN 102234334 B) filed by Synthetix Pharmaceuticals. It discloses a specific type of chimeric protein known as a monomer-dimer heterodimer.

The invention involves a protein comprising two polypeptide chains. The first chain contains a biologically active molecule (such as interferon, erythropoietin, or coagulation factors) linked to an Fc region that acts as an FcRn binding partner. The second chain contains an Fc region that also acts as an FcRn binding partner but does not contain the biologically active molecule or variable regions. This structure is designed to extend the half-life of the active molecule in the body. This manual is written in Chinese.

What's inside

  • 权利要求书
  • 发明名称
  • 摘要
  • 对比文件
  • 专利权人
  • 发明人
  • 申请日
  • 授权公告日

Frequently asked questions

Which bioactive molecules can be part of the chimeric protein?

Interferon, erythropoietin, and clotting factors.

What condition is mentioned for use with interferon?

Viral infection.

What administration routes are listed for the chimeric protein?

Intravenous, subcutaneous, oral, buccal, sublingual, nasal, parenteral, rectal, vaginal, or pulmonary.

What does the second polypeptide chain not contain?

The bioactive molecule and the immunoglobulin variable region.

Download PDF (1.8 MB)

Also Manuals